Dr. Jared D. Acoba
Claim this profileQueen's Medical Center
Studies Colorectal Cancer
Studies Cancer
16 reported clinical trials
36 drugs studied
Area of expertise
1Colorectal Cancer
Stage III
Stage IV
BRAF negative
2Cancer
Stage III
Stage IV
BRAF negative
Affiliated Hospitals
Clinical Trials Jared D. Acoba is currently running
BRAF-Targeted Therapy
for Colon Cancer
This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Giving encorafenib and cetuximab after standard surgery and chemotherapy may be more effective at reducing the chance of cancer recurrence compared to the usual patient observation.
Recruiting1 award Phase 2 & 3
Radiation + Immunotherapy
for Non-Small Cell Lung Cancer
This trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hyperfractionated radiation therapy delivers smaller doses of radiation therapy over time and may kill more tumor cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to test the safety and effectiveness of radiation therapy followed by atezolizumab and find out what side effects, if any, it has on patient's non-small cell lung cancer.
Recruiting1 award Phase 239 criteria
More about Jared D. Acoba
Clinical Trial Related5 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Jared D. Acoba has experience with
- Fluorouracil
- Oxaliplatin
- Leucovorin Calcium
- Irinotecan Hydrochloride
- Atezolizumab
- Irinotecan
Breakdown of trials Jared D. Acoba has run
Colorectal Cancer
Cancer
Colon Cancer
Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jared D. Acoba specialize in?
Jared D. Acoba focuses on Colorectal Cancer and Cancer. In particular, much of their work with Colorectal Cancer has involved Stage III patients, or patients who are Stage IV.
Is Jared D. Acoba currently recruiting for clinical trials?
Yes, Jared D. Acoba is currently recruiting for 6 clinical trials in Honolulu Hawaii. If you're interested in participating, you should apply.
Are there any treatments that Jared D. Acoba has studied deeply?
Yes, Jared D. Acoba has studied treatments such as Fluorouracil, Oxaliplatin, Leucovorin Calcium.
What is the best way to schedule an appointment with Jared D. Acoba?
Apply for one of the trials that Jared D. Acoba is conducting.
What is the office address of Jared D. Acoba?
The office of Jared D. Acoba is located at: Queen's Medical Center, Honolulu, Hawaii 96813 United States. This is the address for their practice at the Queen's Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.